WSGR logoWSGR logo
Jennifer D. Knapp
Partner
Corporate
Palo Alto

D650-849-3041

Download vCard
LinkedIn
Open PDF
  • Comprehensive Corporate and Securities Experience

    Jennifer represents clients in a wide range of corporate compliance and transactional matters, including formation and structuring,  venture financings, corporate governance, spin-ins and spin-outs, mergers and acquisitions, public offerings, public company disclosure requirements, and SEC compliance issues.

  • Represents Innovative Technology Companies and Leading Investors

    Jennifer represents innovative technology and life sciences clients, as well as leading venture capital firms and institutional investors.

Jennifer Knapp represents public and private companies across all stages of growth and a broad range of sectors, as well as venture capital and other institutional investors. She focuses on the representation of companies throughout their entire life cycle from formation to exit, and in all manner of strategic and complex transactions, including corporate formation and structuring, venture capital financings, corporate governance, spin-ins and spin-outs, mergers and acquisitions, public offerings, public company disclosure requirements, and SEC compliance matters. She also has significant experience advising investors with respect to venture capital financings and other strategic investments and transactions.

Experience

Jennifer Knapp represents public and private companies across all stages of growth and a broad range of sectors, as well as venture capital and other institutional investors. She focuses on the representation of companies throughout their entire life cycle from formation to exit, and in all manner of strategic and complex transactions, including corporate formation and structuring, venture capital financings, corporate governance, spin-ins and spin-outs, mergers and acquisitions, public offerings, public company disclosure requirements, and SEC compliance matters. She also has significant experience advising investors with respect to venture capital financings and other strategic investments and transactions.

Focus Areas
Recent Insights
Client Highlights
Wilson Sonsini Advises Enliven Therapeutics on $460 Million Follow-On Offering
On June 15, 2026, Enliven Therapeutics, a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, closed an upsized underwritten public offering of 10,533,334 shares of its common stock, which includes the full exercise of the underwriters' option to purchase 1,600,000 additional shares of its common stock, at a price to the public of $37.50 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 1,733,333 shares of its common stock at a price to the public of $37.499 per pre-funded warrant, which represents the per share public offering price of each share of Enliven Therapeutics' common stock less the $0.001 per share exercise price for each pre-funded warrant. All of the shares and pre-funded warrants were sold by Enliven Therapeutics. The gross proceeds from the offering were approximately $460 million before deducting underwriting discounts and commissions and other offering expenses.
Learn More
Client Highlights
Wilson Sonsini Advises Excellergy on $2 Billion Acquisition by Novartis
On March 27, 2026, Excellergy, a biotechnology company developing a novel class of allergy therapeutics, announced it will be acquired by Novartis in a transaction with a total potential value of up to $2 billion in upfront and milestone payments. The acquisition brings together Excellergy's novel trifunctional ECRIs with the development expertise of Novartis. Wilson Sonsini Goodrich & Rosati advised Excellergy on the transaction.
Learn More
View All
WSGR logo
Copyright © 2026 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.